Structural Basis of Inhibition of the Pioneer Transcription Factor NF-Y by Suramin.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
29 10 2020
Historique:
received: 28 09 2020
revised: 25 10 2020
accepted: 26 10 2020
entrez: 3 11 2020
pubmed: 4 11 2020
medline: 22 6 2021
Statut: epublish

Résumé

NF-Y is a transcription factor (TF) comprising three subunits (NF-YA, NF-YB, NF-YC) that binds with high specificity to the CCAAT sequence, a widespread regulatory element in gene promoters of prosurvival, cell-cycle-promoting, and metabolic genes. Tumor cells undergo "metabolic rewiring" through overexpression of genes involved in such pathways, many of which are under NF-Y control. In addition, NF-YA appears to be overexpressed in many tumor types. Thus, limiting NF-Y activity may represent a desirable anti-cancer strategy, which is an ongoing field of research. With virtual-screening docking simulations on a library of pharmacologically active compounds, we identified suramin as a potential NF-Y inhibitor. We focused on suramin given its high water-solubility that is an important factor for in vitro testing, since NF-Y is sensitive to DMSO. By electrophoretic mobility shift assays (EMSA), isothermal titration calorimetry (ITC), STD NMR, X-ray crystallography, and molecular dynamics (MD) simulations, we showed that suramin binds to the histone fold domains (HFDs) of NF-Y, preventing DNA-binding. Our analyses, provide atomic-level detail on the interaction between suramin and NF-Y and reveal a region of the protein, nearby the suramin-binding site and poorly conserved in other HFD-containing TFs, that may represent a promising starting point for rational design of more specific and potent inhibitors with potential therapeutic applications.

Identifiants

pubmed: 33138093
pii: cells9112370
doi: 10.3390/cells9112370
pmc: PMC7692634
pii:
doi:

Substances chimiques

CCAAT-Binding Factor 0
Transcription Factors 0
nuclear factor Y 0
Suramin 6032D45BEM
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Cell Biol. 2008 Mar;28(6):2047-58
pubmed: 18212061
J Comput Chem. 2004 Jul 15;25(9):1157-74
pubmed: 15116359
Biochim Biophys Acta Gene Regul Mech. 2017 May;1860(5):543-559
pubmed: 27989936
Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
pubmed: 16369096
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31844000
Mol Cell. 2009 Dec 11;36(5):900-11
pubmed: 20005852
Gene. 1999 Oct 18;239(1):15-27
pubmed: 10571030
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
J Bacteriol. 1996 Jul;178(13):3908-16
pubmed: 8682797
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biochim Biophys Acta Gene Regul Mech. 2017 May;1860(5):598-603
pubmed: 27815195
Cell Rep. 2016 Jun 14;15(11):2348-56
pubmed: 27264179
J Biol Chem. 2009 Dec 4;284(49):34189-200
pubmed: 19690168
Pharmacol Rev. 1993 Jun;45(2):177-203
pubmed: 8396782
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
Cancer Chemother Pharmacol. 1993;32(2):96-8
pubmed: 8387401
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Cell Metab. 2008 Jan;7(1):11-20
pubmed: 18177721
Acta Crystallogr D Biol Crystallogr. 2015 Oct;71(Pt 10):2066-78
pubmed: 26457430
Cell. 2013 Jan 17;152(1-2):132-43
pubmed: 23332751
J Med Chem. 2013 Aug 22;56(16):6339-51
pubmed: 23889553
Nat Protoc. 2016 May;11(5):882-94
pubmed: 27055097
Structure. 2012 Oct 10;20(10):1757-68
pubmed: 22902862
Int J Cancer. 2003 Mar 20;104(2):167-74
pubmed: 12569571
Dev Biol. 2007 Aug 15;308(2):583-92
pubmed: 17574230
Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118571
pubmed: 31706909
Biochim Biophys Acta Gene Regul Mech. 2017 May;1860(5):617-629
pubmed: 27750031
Cancer Res. 1999 Jul 15;59(14):3433-41
pubmed: 10416607
Chronic Dis Transl Med. 2018 Oct 23;5(1):44-52
pubmed: 30993263
Bioorg Med Chem. 2008 Feb 15;16(4):2093-102
pubmed: 17977733
Cell Death Differ. 2013 May;20(5):676-85
pubmed: 23449390
J Biol Chem. 2003 Jan 10;278(2):1336-45
pubmed: 12401788
J Struct Biol. 2011 Aug;175(2):178-88
pubmed: 21320604
Biophys J. 2008 Oct;95(7):3366-80
pubmed: 18586854
Oncotarget. 2017 Jan 31;8(5):7935-7945
pubmed: 27974701
Mol Gen Genet. 1992 Oct;235(1):81-8
pubmed: 1435733
Oncotarget. 2016 Jan 12;7(2):1633-50
pubmed: 26646448
Mol Cancer Ther. 2007 Jan;6(1):346-54
pubmed: 17237293
Genes (Basel). 2020 Feb 14;11(2):
pubmed: 32075093
FASEB J. 2019 Apr;33(4):4790-4801
pubmed: 30589568
Gene. 2007 Mar 1;389(1):52-65
pubmed: 17123746
Science. 1984 Oct 12;226(4671):172-4
pubmed: 6091268
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Plant J. 2020 Oct 24;:
pubmed: 33098724
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Clin Cancer Res. 2003 Aug 15;9(9):3303-11
pubmed: 12960116
Oncotarget. 2017 Apr 4;8(14):22370-22384
pubmed: 26517684
Angew Chem Int Ed Engl. 1999 Jun 14;38(12):1784-1788
pubmed: 29711196
Proteins. 2006 Nov 15;65(3):712-25
pubmed: 16981200
FEBS Lett. 2014 Aug 19;588(16):2622-7
pubmed: 24768524
Angew Chem Int Ed Engl. 2019 Nov 25;58(48):17351-17358
pubmed: 31539186
Acta Crystallogr D Biol Crystallogr. 2004 Mar;60(Pt 3):432-8
pubmed: 14993666
Protein Eng. 1995 Feb;8(2):127-34
pubmed: 7630882
Mol Cancer Ther. 2008 May;7(5):1319-28
pubmed: 18483319
Cancer Res. 1995 Nov 1;55(21):4957-61
pubmed: 7585536
Cell Cycle. 2009 Dec 15;8(24):4127-37
pubmed: 19946211
J Mol Biol. 2001 Mar 2;306(4):643-53
pubmed: 11243777
Cancer Cell. 2008 Jun;13(6):472-82
pubmed: 18538731
Sci Rep. 2019 Sep 10;9(1):12955
pubmed: 31506469
Bioorg Med Chem. 2010 Aug 1;18(15):5553-61
pubmed: 20615712
J Chem Phys. 2007 Jan 7;126(1):014101
pubmed: 17212484
Eur J Biochem. 1996 Jun 15;238(3):675-82
pubmed: 8706667
Genes (Basel). 2019 Nov 17;10(11):
pubmed: 31744190
Transcription. 2013 May-Jun;4(3):114-9
pubmed: 23756340
Structure. 2007 Mar;15(3):377-89
pubmed: 17355872
J Biol Chem. 1991 May 25;266(15):9661-6
pubmed: 2033058

Auteurs

Valentina Nardone (V)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Antonio Chaves-Sanjuan (A)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Michela Lapi (M)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Cristina Airoldi (C)

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy.

Andrea Saponaro (A)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Sebastiano Pasqualato (S)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139 Milan, Italy.

Diletta Dolfini (D)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Carlo Camilloni (C)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Andrea Bernardini (A)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Nerina Gnesutta (N)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Roberto Mantovani (R)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Marco Nardini (M)

Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH